Federal Trade Commission v. Actavis, Inc. and Reverse-Payment or Pay-for-Delay Settlements

Nature Biotechnology, Vol. 31, p. 316, 2013

Stanford Public Law Working Paper No. 2296187

2 Pages Posted: 20 Jul 2013 Last revised: 26 Feb 2014

See all articles by Jacob S. Sherkow

Jacob S. Sherkow

New York Law School; Columbia University - Department of Health Policy and Management; Center for Advanced Studies in Biomedical Innovation Law

Date Written: April 1, 2013

Abstract

An imminent US Supreme Court ruling should resolve one of the thorniest legal issues facing pharmaceutical companies today.

Keywords: antitrust, patent, intellectual property, settlement, pharmaceutical, biotechnology

JEL Classification: K00, K11, K1, K41, O34, O38

Suggested Citation

Sherkow, Jacob S., Federal Trade Commission v. Actavis, Inc. and Reverse-Payment or Pay-for-Delay Settlements (April 1, 2013). Nature Biotechnology, Vol. 31, p. 316, 2013; Stanford Public Law Working Paper No. 2296187. Available at SSRN: https://ssrn.com/abstract=2296187

Jacob S. Sherkow (Contact Author)

New York Law School ( email )

185 West Broadway
New York, NY 10013
United States
212.431.2355 (Phone)

HOME PAGE: http://www.nyls.edu/faculty/faculty-profiles/faculty_profiles/jacob-s-sherkow/

Columbia University - Department of Health Policy and Management ( email )

600 West 168th Street, 6th Floor
New York, NY 10032
United States

Center for Advanced Studies in Biomedical Innovation Law ( email )

Studiestraede 6
Studiestrade 6
Copenhagen, DK-1455
Denmark

HOME PAGE: http://jura.ku.dk/cebil/staff/

Register to save articles to
your library

Register

Paper statistics

Downloads
65
Abstract Views
409
rank
336,806
PlumX Metrics